{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:04:52Z","timestamp":1791644692680,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003284","name":"Pulmonary Fibrosis Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100003284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pragmatic use of the anti-fibrotic medications pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) in the United States (US) has not been studied and may be different from international settings due to structural differences between health care systems. This study examined the relationship between patient- and site-level characteristics and anti-fibrotic (a) use and (b) selection.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Data from the Pulmonary Fibrosis Foundation Patient Registry was used to perform univariable and multivariable regressions with generalized linear mixed models. A random effects model examined registry site variation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>703 of 1218 (57.7%) patients were taking a single anti-fibrotic of which 312 (44.4%) were taking nintedanib and 391 (55.6%) were taking pirfenidone. Up to 25% of patients using an anti-fibrotic may have been excluded from clinical trial participation due to having too severe disease as measured by diffusion limitation for carbon monoxide. Age (OR\u2009=\u20090.974, <jats:italic>p<\/jats:italic>\u2009=\u20090.0086) and diffusion capacity of the lungs for carbon monoxide (per 10% increase in percent-predicted; OR\u2009=\u20090.896, <jats:italic>p<\/jats:italic>\u2009=\u20090.0007) was negatively associated with anti-fibrotic use while time (in log of days) since diagnosis (OR\u2009=\u20091.138, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), recent patient clinical trial participation (OR\u2009=\u20091.569, <jats:italic>p<\/jats:italic>\u2009=\u20090.0433) and oxygen use (OR\u2009=\u20091.604, <jats:italic>p<\/jats:italic>\u2009=\u20090.0027) was positively associated with anti-fibrotic use. Time (log of days) since diagnosis (OR\u2009=\u20091.075, <jats:italic>p<\/jats:italic>\u2009=\u20090.0477), history of coronary artery disease (OR\u2009=\u20091.796, <jats:italic>p<\/jats:italic>\u2009=\u20090.0030), presence of pulmonary hypertension (OR\u2009=\u20092.139, <jats:italic>p<\/jats:italic>\u2009=\u20090.0376), patient clinical trial participation in the prior 12\u2009months (OR\u2009=\u20092.485, <jats:italic>p<\/jats:italic>\u2009=\u20090.0002), diffusion capacity of the lungs for carbon monoxide (per 10% increase in percent-predicted; OR\u2009=\u20091.138, <jats:italic>p<\/jats:italic>\u2009=\u20090.0184), anticoagulant use (OR\u2009=\u20092.507, <jats:italic>p<\/jats:italic>\u2009=\u20090.0028), and enrollment at a registry site in the Midwest region (OR\u2009=\u20091.600, <jats:italic>p<\/jats:italic>\u2009=\u20090.0446) were associated with pirfenidone use. Anti-fibrotic use varied by registry site. Rates of discontinuation were modest and nearly identical for the two medications with side effects being the most common reason given for discontinuation. Twenty-three percent (23%, 274) of persons with IPF were using or had recently used an immunomodulatory agent.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This analysis provides a detailed characterization of IPF treatment patterns in the US; many users of anti-fibrotic medications may not have qualified for inclusion in clinical trials. More research is needed to understand variations in medical decision-making for use and selection of anti-fibrotic medication.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-020-1315-4","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T18:03:10Z","timestamp":1581357790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-9874","authenticated-orcid":false,"given":"Colin H.","family":"Holtze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Freiheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Limb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Raimundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne T.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"issue":"22","key":"1315_CR1","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"1315_CR2","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"key":"1315_CR3","doi-asserted-by":"crossref","unstructured":"Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, et al. Patient registries in idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med. 2019.","DOI":"10.1164\/rccm.201902-0431CI"},{"issue":"2","key":"1315_CR4","doi-asserted-by":"publisher","first-page":"1601592","DOI":"10.1183\/13993003.01592-2016","volume":"49","author":"Helen E. Jo","year":"2017","unstructured":"Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49(2). https:\/\/doi.org\/10.1183\/13993003.01592-2016.","journal-title":"European Respiratory Journal"},{"issue":"1","key":"1315_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","volume":"19","author":"A Guenther","year":"2018","unstructured":"Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):141.","journal-title":"Respir Res"},{"issue":"1","key":"1315_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/09031936.00217614","volume":"46","author":"J Behr","year":"2015","unstructured":"Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46(1):186\u201396.","journal-title":"Eur Respir J"},{"issue":"1","key":"1315_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000331","volume":"5","author":"WA Wuyts","year":"2018","unstructured":"Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, et al. Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. BMJ Open Respir Res. 2018;5(1):e000331.","journal-title":"BMJ Open Respir Res"},{"key":"1315_CR8","doi-asserted-by":"crossref","unstructured":"Bargagli E, Piccioli C, Rosi E, Torricelli E, Turi L, Piccioli E, et al. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: real-life experience in an Italian referral Centre. Pulmonology. 2018.","DOI":"10.1016\/j.pulmoe.2018.06.003"},{"key":"1315_CR9","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3389\/fphar.2018.01480","volume":"9","author":"SL Barratt","year":"2018","unstructured":"Barratt SL, Mulholland S, Al Jbour K, Steer H, Gutsche M, Foley N, et al. South-west of England's experience of the safety and tolerability Pirfenidone and Nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). Front Pharmacol. 2018;9:1480.","journal-title":"Front Pharmacol"},{"key":"1315_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1159\/000490667","volume":"96","author":"TM Maher","year":"2018","unstructured":"Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, et al. Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views. Respiration. 2018;96:514\u201324.","journal-title":"Respiration"},{"issue":"1","key":"1315_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","volume":"159","author":"JL Hankinson","year":"1999","unstructured":"Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179\u201387.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1315_CR12","first-page":"185","volume":"123","author":"RO Crapo","year":"1981","unstructured":"Crapo RO, Morris AH. Standardized single breath Normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis. 1981;123(2):185\u20139.","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"1315_CR13","first-page":"1121","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus Erythematosus. JAMA Neurology. 1989;46(10):1121\u20133.","journal-title":"JAMA Neurology"},{"issue":"4","key":"1315_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thorax.58.4.339","volume":"58","author":"SS Birring","year":"2003","unstructured":"Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester cough questionnaire (LCQ). Thorax. 2003;58(4):339\u201343.","journal-title":"Thorax."},{"issue":"3","key":"1315_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1378\/chest.113.3.619","volume":"113","author":"EG Eakin","year":"1998","unstructured":"Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD shortness of breath questionnaire. Chest. 1998;113(3):619\u201324.","journal-title":"Chest."},{"issue":"9779","key":"1315_CR16","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London, England). 2011;377(9779):1760\u20139.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"1315_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/jech.2004.029454","volume":"60","author":"J Merlo","year":"2006","unstructured":"Merlo J, Chaix B, Ohlsson H, Beckman A, Johnell K, Hjerpe P, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health. 2006;60(4):290\u20137.","journal-title":"J Epidemiol Community Health"},{"issue":"7","key":"1315_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1513\/AnnalsATS.201810-720RL","volume":"16","author":"TM Maher","year":"2019","unstructured":"Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, et al. Pirfenidone treatment in individuals with idiopathic pulmonary fibrosis: impact of timing of treatment initiation. Ann Am Thorac Soc. 2019;16(7):927\u201330.","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"1315_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1164\/rccm.201501-0172OC","volume":"192","author":"YM Arabi","year":"2015","unstructured":"Arabi YM, Cook DJ, Zhou Q, Smith O, Hand L, Turgeon AF, et al. Characteristics and outcomes of eligible nonenrolled patients in a mechanical ventilation trial of Acute respiratory distress syndrome. Am J Respir Crit Care Med. 2015;192(11):1306\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1315_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","volume":"200","author":"TM Dempsey","year":"2019","unstructured":"Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of Antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1315_CR21","doi-asserted-by":"publisher","first-page":"1801797","DOI":"10.1183\/13993003.01797-2018","volume":"54","author":"Imre Noth","year":"2019","unstructured":"Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019;54(3). https:\/\/doi.org\/10.1183\/13993003.01797-2018.","journal-title":"European Respiratory Journal"},{"issue":"4","key":"1315_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12325-014-0112-1","volume":"31","author":"U Costabel","year":"2014","unstructured":"Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375\u201391.","journal-title":"Adv Ther"},{"key":"1315_CR23","doi-asserted-by":"crossref","unstructured":"Blumthaler M. UV Monitoring for Public Health. International journal of environmental research and public health. 2018;15(8).","DOI":"10.3390\/ijerph15081723"},{"issue":"2","key":"1315_CR24","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u2013e19.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1315_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","volume":"196","author":"B Ley","year":"2017","unstructured":"Ley B, Swigris J, Day B-m, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756\u201361.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-1315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-020-1315-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-1315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:40:55Z","timestamp":1612834855000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-1315-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-1315-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"18 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The PFF-PR study was reviewed and approved by the institutional review boards at each registry site, and patient participants signed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CH is supported by NIH Grant No. T32 HL007749\u201326. EF is a managing director of the SABER unit within the department of biostatistics at the University of Michigan. SABER receives funding from the Pulmonary Fibrosis Foundation. JS, SL and KR are employees of Genentech. WP is a former employee of Genentech. He is currently employed at BioMarin. KF reports personal fees from Veracyte and Sanofi Genzyme; and grants and personal fees from Roche\/Genentech and Boehringer Ingelheim, outside of the submitted work. HK has served as site principle investigator for IPF clinical trials sponsored by InterMune, Gilead, Sanofi, Celgene, and Centocor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}